Halozyme Therapeutics, Inc. $HALO Shares Acquired by Faithward Advisors LLC

Key Points

• Faithward Advisors LLC sharply increased its Halozyme stake by 174.8% in Q1, buying 40,333 more shares and bringing its total to 63,403 shares worth about $4.1 million.
• Analyst sentiment remains mostly positive: several firms reiterated or upgraded to Buy, and the stock has a consensus rating of Moderate Buy with an average target price of $81.60.
• Halozyme reported better-than-expected Q1 earnings of $1.60 per share on revenue of $376.7 million, while insiders also disclosed recent sales, including CEO Helen Torley’s 20,000-share sale under a 10b5-1 plan.

Faithward Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 174.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 63,403 shares of the biopharmaceutical company's stock after purchasing an additional 40,333 shares during the quarter. Faithward Advisors LLC owned about 0.05% of Halozyme Therapeutics worth $4,098,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC raised its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the period. Abel Hall LLC boosted its position in shares of Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company's stock worth $216,000 after buying an additional 129 shares during the period. StoneX Group Inc. grew its stake in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company's stock valued at $246,000 after buying an additional 132 shares in the last quarter. Moran Wealth Management LLC grew its stake in shares of Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company's stock valued at $2,396,000 after buying an additional 151 shares in the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in shares of Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company's stock valued at $654,000 after buying an additional 165 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. UBS Group reissued a "buy" rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $81.60.

Halozyme Therapeutics Stock Performance

HALO stock opened at $69.62 on Wednesday. The stock's 50 day simple moving average is $68.10 and its 200 day simple moving average is $68.69. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The firm has a market cap of $8.26 billion, a P/E ratio of 25.04, a P/E/G ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the prior year, the firm earned $1.11 EPS. The company's revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares in the company, valued at approximately $2,891,324.49. This trade represents a 3.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 93,250 shares of company stock valued at $6,299,746. Corporate insiders own 2.50% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.